subscribeSubscribe
Novugen`s Generic Pazopanib Hydrochloride Receives Approval in the U.S.

Novugen`s Generic Pazopanib Hydrochloride Receives Approval in the U.S.

FDA
24 Apr 2024
Share Share
Enforcement Report - Week of December 20, 2023

Enforcement Report - Week of December 20, 2023
FDA
20 Dec 2023
Share Share
Sun Pharma`s Generic Pazopanib Receives Approval in the U.S.

Sun Pharma`s Generic Pazopanib Receives Approval in the U.S.
FDA
19 Oct 2023
Share Share
Teva Pharma`s Generic Pazopanib Receives Approval in the U.S.

Teva Pharma`s Generic Pazopanib Receives Approval in the U.S.
FDA
19 Oct 2023
Share Share
Health Canda Issues Recall of Pharmascience`s PMS-Pazopanib 200 mg tablet

Health Canda Issues Recall of Pharmascience`s PMS-Pazopanib 200 mg tablet
HEALTH CANADA
31 May 2023
Share Share
Xynomic Pharma Achieves Important Regulatory Milestones in China and EU

Xynomic Pharma Achieves Important Regulatory Milestones in China and EU
PR NEWSWIRE
18 Mar 2019
Share Share
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts

Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts
Angus Liu FIERCE PHARMA
11 Oct 2018
Share Share
Xynomic preps broad push for HDAC cancer drug

Xynomic preps broad push for HDAC cancer drug
Phil Taylor FIERCE BIOTECH
01 Jun 2018
Share Share
Novartis to Present a Whopping 84 Abstracts at ASCO and EHA

Novartis to Present a Whopping 84 Abstracts at ASCO and EHA
Mark Terry BIOSPACE
17 May 2018
Share Share
AGRX Fails To SECURE Investor Confidence, ITEK Hit Hard, CBAY Rises On Kowa Deal

AGRX Fails To SECURE Investor Confidence, ITEK Hit Hard, CBAY Rises On Kowa Deal
NASDAQ
04 Jan 2017
Share Share